Accretion Pharmaceuticals Ltd
NSE: ACCPL
₹171.80
₹7.70
(4.69%)
As on 23-Jul-2026 15:26IST
Market cap
₹182 Cr
Revenue (TTM)
₹57 Cr
P/E Ratio
18.9
P/B Ratio
3.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹7 Cr
-
ROE
65.4 %
-
ROCE
46.3 %
-
Industry P/E
39.7
-
EV/EBITDA
13
-
Debt to Equity
0.9
-
Book Value
₹18.7
-
EPS
₹8.3
-
Face value
10
-
Shares outstanding
11,116,000
Years Aggregate
CFO
₹--
EBITDA
₹--
Net Profit
₹--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
| 95.6 | 21.3 | 84.7 | 165.5 | -- | -- | -- |
|
BSE Healthcare
| 14.1 | 2.8 | 13.9 | 10.9 | 22.9 | 13.5 | 11.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
171.8 | 182.4 | 57.4 | 6.8 | -- | 65.4 | 18.9 | 3.3 |
| 3,428.9 | 28,568.1 | 1,339.4 | 356.4 | 33.2 | 23.2 | 80.2 | 17.3 | |
| 421.5 | 16,370.1 | 2,268.6 | 150.1 | 10.6 | 5.4 | 91.3 | 4.2 | |
| 852.9 | 21,308.1 | 5,632.3 | 662.4 | 17.2 | 14.3 | 32.2 | 4.3 | |
| 918.3 | 16,715.4 | 4,078.3 | 1,371.9 | 30.2 | 15.9 | 11.8 | 1.8 | |
| 1,649.5 | 18,933.2 | 1,421.6 | -73.8 | 1.8 | -1.1 | -- | 3.2 | |
| 180.8 | 24,370.3 | 8,869.1 | -325.9 | 1.0 | -4 | -- | 3.0 | |
| 1,528.7 | 25,237.8 | 1,284.3 | 134.4 | -- | 30.7 | 102.3 | 19.6 | |
| 404.5 | 16,312.3 | 3,738.7 | 316.7 | 12.5 | 6.7 | 51.5 | 3.4 | |
| 1,848.0 | 30,490.0 | 3,373.0 | 199.0 | 12.6 | 4.3 | 143.1 | 6.2 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Accretion Pharmaceuticals
--
-
Incorporated
2023
-
Chairman
Harshad Nanubhai Rathod
-
Managing Director
Vivek Ashok Kumar Patel
-
Headquarters
Ahmedabad, Gujarat
-
Website
Looking for more details about Accretion Pharmaceuticals Ltd’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Accretion Pharmaceuticals
What is the current share price of Accretion Pharmaceuticals Ltd Today?
The share price of Accretion Pharmaceuticals Ltd is ₹171.80 (NSE) as of 23-Jul-2026 15:26 IST. Accretion Pharmaceuticals Ltd has given a return of 165.53% in the last 1 years.
What is the current PB & PE ratio of Accretion Pharmaceuticals Ltd?
The P/E ratio of Accretion Pharmaceuticals Ltd is 18.87 times as on 22-Jul-2026, a 52 discount to its peers’ median range of 39.70 times.
The P/B ratio of Accretion Pharmaceuticals Ltd is 3.33 times as on 22-Jul-2026, a 10 discount to its peers’ median range of 3.72 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
0.00
|
|
2024
|
0.00
|
0.00
|
|
2025
|
0.00
|
0.00
|
|
2024
|
0.00
|
0.00
|
What is the 52 Week High and Low of Accretion Pharmaceuticals Ltd?
The 52-week high and low of Accretion Pharmaceuticals Ltd are Rs 171.80 and Rs 53.80 as of 23-Jul-2026.
What is the market cap of Accretion Pharmaceuticals Ltd?
Accretion Pharmaceuticals Ltd has a market capitalisation of ₹ 182 Cr as on 22-Jul-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Accretion Pharmaceuticals Ltd?
Before investing in Accretion Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.